Main Topics

Fam-trastuzumab deruxtecan-nxki is approved by FDA for breast cancer

April 2022: Adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the...

Pluvicto is approved by FDA for metastatic castration-resistant prostate cancer

April 2022: The Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a Novartis company) for the treatment...

Pembrolizumab is approved for advanced endometrial carcinoma

April 2022: Pembrolizumab (Keytruda, Merck) was approved by the Food and Drug Administration as a single agent for patients with advanced endometrial carcinoma that is microsatellite...

First LAG-3-Blocking antibody combination, Opdualag™ (nivolumab and relatlimab-rmbw), is approved by FDA for patients with unresectable or metastatic melanoma

April 2022: The US Food and Drug Administration (FDA) has approved Opdualag (nivolumab and relatlimab-rmbw), a new, first-in-class fixed-dose combination of nivolumab and relatlimab administered...

JW Therapeutics’ IND is cleared by China NMPA for CAR T-Cell therapy in large B-Cell lymphoma

China’s National Medical Products Administration (NMPA) has approved JW Therapeutics’ investigational new drug (IND) application for a key clinical trial of Carteyva (relmacabtagene autoleucel) in...

Can CAR T-Cell manufacturing time be reduced to just one day?

April 2022: Normally, the cell manufacturing procedure for CAR T-cell therapy takes nine to fourteen days; however, researchers at the University of Pennsylvania were able...

CAR T-Cell therapy in solid tumors – A research study

March 2022: Blood vessels are supposed to behave like trees, pouring oxygen into tissues in order for them to flourish and immune cells to clean...

CAR T- cell therapy for breast cancer is on the cards

March 2022: According to researchers at the UNC Lineberger Comprehensive Cancer Center, adding a tiny chemical to a treatment process called chimeric antigen receptor-T (CAR-T) cell...

Childhood leukemia and its treatment

Leukemia in childhood Leukemia is the most common cancer in children and teens, accounting for almost 1 out of 3 cancers. Most childhood leukemias are...

CARVYKTI (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, receives U.S. FDA approval for the treatment of adult patients with relapsed or refractory multiple myeloma

March 2022: According to Johnson & Johnson, a therapy developed by the company and its China-based partner Legend Biotech Corp to treat a kind of white blood...

High Intensity Focused Ultrasound

March 2022: HIFU (High Intensity Focused Ultrasound) is a cutting-edge therapy that uses focused, high-energy ultrasound waves to heat and kill cancerous parts of the...

CAR-T Cell therapy could be made safer and more widely available with a few adjustments

March 2022: A revolutionary approach to CAR-T Cell therapy has the potential to overturn what has become a medical axiom: that the treatment’s remarkable effect...

Need help? Our team is ready to assist you.

We wish a speedy recovery for your loved ones.

Scan the code